Cancer Genomics 2017 invites all the participants from all over the world to attend 10th International Conference on Cancer Genomics during November 2-3, 2017 Toronto, Canada which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Cancer Genomics 2017 is an area within genomics that concerns the genetic mutations responsible for Cancer using genome sequencing and bioinformatics. The fields of Cancer Biology and Genetics are mainly concerned with the study of the role and function of single genes, a major topic in today’s biomedical research.
Why to attend???
With members from around the world focused on learning about Cancer Genomics and its advances in Diagnosis, Treatment, Prevention; this is your best opportunity to reach the largest assemblage of participants from the Cancer Genomics and its allied areas. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates, n Cancer Genomics are hallmarks of this conference.
- Cancer Researchers
- Oncology Faculty
- Genomic Students
- Genomics Researchers
- Genomics Faculty
- Genomics Scientists
- Genomics Colleges
- Pharmacology Scientists
- Pharmacology Health Professionals
- Genetics Associations and Societies
- Genetic Counselors
- Business Entrepreneurs
- Training Institutes
- Software developing companies
- Data Management Companies
Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Sessions $ Tracks
Theranostics – a combination of the words therapeutics and diagnostics – describes a treatment platform that combines a diagnostic test with targeted therapy based on the test results, i.e. a step towards personalized medicine. Making use of nanotechnology materials and applications, theranostic nanomedicine can be understood as an integrated nanotherapeutic system, which can diagnose, deliver targeted cancer therapy and monitor the response to therapy.
Track: 2 Whole Genome Sequencing
Whole genome sequencing also known as full genome sequencing, complete genome sequencing, or entire genome sequencing is a laboratory process that determines the complete DNA sequence of an organism's genome at a single time.
Track: 3 Stem cells- Cancer
One of the most exciting recent developments in the field of cancer biology is the recognition that lineage progression continues to occur in tumours. In particular, there is an increasing body of evidence that like normaltissues, tumor cells that have the potential for unlimited self-renewal give rise in large numbers to cells that lack this potential - the so-called cancer stem cell hypothesis. By focusing for so many years on the majority cell populations in tumors, and not on the rarer cancer stem cells (cancer initiating cells), scientists and clinicians may have missed out on opportunities to understand, diagnose and treat the processes in cancer that matter most.
Track: 4 Trends in Cancer Genomics
The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer- Progress in DNA sequencing has revealed the startling complexity of cancer genomes, which typically carry thousands of somatic mutations. Large-scale cancer genomics has further established a baseline that is now poised to effect the translation ofcancer genomics into the clinical setting, effectively transforming patient care. The barriers and challenges totranslation are significant, not the least of which involves the transition of research-grade computational and interpretational analysis to clinical-grade analysis.
Track: 5 Cancer Biopsy
Cancer is a heterogeneous genetic disease, and excisional biopsies provide only a snapshot in time of some of the rapid, dynamic genetic changes occurring in tumors. In addition, excisional biopsies are invasive, can’t be used repeatedly, and are ineffective in understanding the dynamics of tumor progression and metastasis. However, liquid biopsy, or blood-sample tests, under development by Epic Sciences can generate actionable information for oncologists by analyzing circulating tumor cells (CTCs) and fragments of tumor-cell DNA that are continuously shed by tumors into the bloodstream.
Track: 6 Cancer Genome Therapy
Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases. These studies highlight the opportunity for strategies to achieve truly personalized cancer treatment. Particularly important has been the use of genome-scale gene expression analyses to identify discrete disease classes not previously recognized.
Track: 7 Epigenetics and cancer genomics
The field of cancer epigenetics is evolving rapidly on several fronts. Advances in our understanding of chromatin structure, histone modification, transcriptional activity and DNA methylation have resulted in an increasingly integrated view of epigenetics. In response to these insights, epigenetic therapy is expanding to include combinations of histone deacetylase inhibitors and DNA methyltransferase inhibitors.
Track: 8 Cancer Nanotechnology
Nanotechnology is increasingly finding use in the management of cancer. Nanoscale devices have impactedcancer biology at three levels: early detection using, for example, Nano cantilevers or nanoparticles; tumour imaging using radio contrast nanoparticles or quantum dots; and drug delivery using nanovectors and hybrid nanoparticles.
Track: 9 Hormone-Dependent Cancers
Hormones influence not only breast and prostate cancer, the two most common hormone-dependent cancers, but also have a major impact on less common hormone-sensitive malignancies (e.g. ovary, testes, endometrium) as well as human cancers recently discovered to be hormone sensitive (e.g. lung, liver).
Track: 10 Frontiers in Gene Editing
Gene editing is rapidly progressing from being a research/ screening tool to one that promises important applications downstream in drug development, cell therapy and bioprocessing. Genome editing is now a new trend in 2016. The engineered editing system makes use of an enzyme that nicks together DNA with a piece ofsmall RNA that guides the tool to where researchers want to introduce cuts or other changes in the genome.
Track: 11 Big Data in Cancer Genomics
Several recently announced collaborations between academic research institutions and big data analytics vendors powering advanced discovery technologies will bring the power of big data to new studies that may have significant impacts on future therapies and treatments. With oncology and genomics in the spotlight,personalized medicine is poised to take a leap forward as researchers dive into complex diseases. By analysing data from multiple cancer types, we could evaluate prognostic models and identify gene alterations that led to tumor formation. This wouldn’t have been obtained by looking at tumor data from just one cancer type.
Track: 12 Cell fate in cancer
The cell is the basic unit of life. The attainment of a nucleus to house the genetic material is thought to have provided a distinct advantage to the evolving cell, ultimately allowing the emergence of differentiated, specialized cells. Hoarding evidence suggests that genomes are organized non-randomly into complex 3D configurations that vary according to cell type, stage of development, differentiation and disease status. The principles, which guide higher order organization, the mechanisms responsible for establishment, maintenance and alterations of higher order genome, and the functional consequences of aberrant genome and nuclear organization, have become zones of intense interest.